EcoSta 2018: Registration
View Submission - EcoSta2018
Title: Adaptive design of clinical trials Authors:  Xikui Wang - University of Manitoba (Canada) [presenting]
Abstract: The use of adaptive design in Phases I and III clinical trials, particularly following the Bayesian and other approaches, is discussed. The design of Phase I clinical trials is adaptive in nature, and the goal of the design is to search for the maximum tolerated dose while controlling the overall toxicity of all patients in the trial. On the other hand, the goal of response adaptive design of Phase III clinical trials is to maximize the individual ethics while safeguarding the collective ethics. The nature of the adaptive design is the balance between exploration and exploitation according to a certain optimality criterion, which reflects upon the trade-off between the individual ethics of all patients in the trial and the collective ethics of the general public. We will discuss different adaptive designs of clinical trials.